The Global IPO Market1. What Is an IPO & Why It Matters
An Initial Public Offering (IPO) is when a private company offers its shares to the public for the first time by listing on a stock exchange. It allows companies to raise capital from a broad investor base, provides liquidity to early investors and employees, and increases visibility and credibility. In return, public markets demand transparency, regulatory compliance, and ongoing disclosure.
IPOs serve as a crucial mechanism in global finance for capital formation, enabling companies to fund expansion, repay debt, invest in research and development, and pursue acquisitions. For investors, IPOs can offer growth opportunities—especially if the company scales rapidly post‑listing.
2. How the Global IPO Market Works
Key Participants
Issuing Company (Issuer): Seeks capital through a public listing.
Underwriters/Investment Banks: Advise on pricing, structure the deal, and sell shares to institutional and retail investors.
Stock Exchanges: Provide the platform for listing (e.g., NYSE, Nasdaq, HKEX).
Regulators: Oversee disclosure and compliance (e.g., SEC in the U.S.).
Investors: Institutional (mutual funds, hedge funds) and retail investors who buy shares.
Process Overview
Preparation: Financial audits, governance structures, and prospectus creation.
Due Diligence: Underwriters evaluate company financials and market potential.
Marketing (Roadshow): Presenting the investment case to potential investors.
Pricing: Shares are priced based on demand and valuation metrics.
Listing: Shares begin trading publicly, often with first‑day “pop” or volatility.
The success of an IPO depends on market conditions, investor appetite, sector momentum, and broader economic trends.
3. Current Trends in the Global IPO Market (2025)
Overall Market Health
After years of caution driven by geopolitical tensions, interest rate uncertainty, and volatility, 2025 saw a stabilizing and resilient global IPO market. According to data from EY’s Global IPO Trends, there were approximately 1,293 IPOs raising US$171.8 billion globally in 2025, signaling renewed confidence and a shift toward higher‑quality offerings.
This continues a trend of recovery following slow periods in 2022–24. While not yet at the frothy peaks of the 2021 boom, IPO markets are showing strength characterized by larger deal sizes and selective investor interest in standout companies.
Volume vs. Proceeds
Data indicates that while the number of IPOs hasn’t surged dramatically, total capital raised is increasing—reflecting a shift toward larger, more established issuers deciding to go public rather than many small firms. This is a key metric of market maturity and investor selectivity.
Cross‑Border Listings
Companies increasingly choose to list on foreign exchanges—a trend especially evident in the U.S. This can enhance liquidity and broaden the investor base. Cross‑border IPOs reached multi‑decade highs in 2025, highlighting globalization within equity capital markets.
Sector Focus
Major IPO activity is concentrated in sectors that attract investor interest, such as:
Technology & AI: Companies tied to digital transformation.
Fintech: Financial technology firms tapping broader capital markets.
Healthcare & Life Sciences: Biotech and life science companies.
Industrials & Consumer Goods: Established firms with strong growth plans.
4. Regional Dynamics
Asia‑Pacific
Asia continues to be a powerhouse in IPO activity.
Greater China (including Hong Kong and mainland China) has emerged as a dominant source of IPO proceeds, capturing around one‑third of global capital raised in the first half of 2025.
Hong Kong Exchange (HKEX) has enjoyed strong listings in 2025, with companies raising significant capital — reflecting confidence in Asia’s public markets.
India has also shown strong IPO volume and improvement in fundraising, trending toward record years and ranking among the top global IPO markets.
This reflects broader economic growth in the region, deepening equity markets, and policy frameworks aimed at attracting listings.
United States
The U.S. traditionally leads global IPO markets in capital raised thanks to large tech and growth company listings:
The U.S. recorded strong IPO volumes in early to mid‑2025—the highest since 2021 in some quarters.
Some of the most anticipated potential IPOs (e.g., SpaceX) could redefine market scale if they materialize.
However, intermittent challenges like regulatory slowdowns (e.g., government shutdowns affecting the SEC) have occasionally slowed the pace of launches.
Europe
Europe’s IPO market remains smaller relative to Asia and the U.S. but showed record momentum at the start of 2026 with major industrial and defense listings.
Emerging Markets
Latin America, the Middle East, and other emerging regions see sporadic but noteworthy IPOs, with firms choosing international listings to access deeper capital pools.
5. Major Recent IPOs & Signals
2026 Activity Indicators
Even in early 2026, new signs of life include:
PicPay’s Nasdaq IPO marking a return of Brazilian companies to public markets after a multi‑year break.
Agibank’s planned U.S. IPO underlining fintech interest from Latin America.
Busy Ming’s successful Hong Kong IPO showing continued appeal of Asian listings.
These signals reflect a nuanced landscape where IPOs are widely spread across sectors and geographies.
6. Challenges Facing the IPO Market
Despite improvements, the global IPO market faces several persistent challenges:
Market Volatility & Economic Uncertainty
Global macroeconomic uncertainty—driven by tariffs, interest rate shifts, and geopolitical tensions—has made companies more cautious about listing timing.
Regulatory & Compliance Pressures
Companies face rising compliance costs and investor demands for transparency and ESG (environmental, social, governance) disclosures—both prerequisites for modern listings.
Investor Selectivity
Investors increasingly focus on firm quality, profitability pathways, and sustainability of growth. Firms with weak fundamentals or unclear growth prospects often delay or cancel IPO plans.
Valuation Concerns
High valuation expectations by private companies sometimes misalign with market realities, leading to postponed listings or sub‑par performances post‑IPO.
7. The Future Outlook
The outlook for the global IPO market remains cautiously optimistic, with several key forces shaping its trajectory:
Strong Pipelines
Many large private companies (especially in tech, fintech, and biotech) remain IPO candidates. As markets stabilize, these firms may enter public markets—potentially providing a meaningful uplift to aggregate proceeds.
Innovation & New Sectors
New sectors like AI, green tech, and biotech are attracting investors and may lead to new high‑value IPOs.
Geographic Shifts
Asia’s increasing share and cross‑border listings suggest a more balanced global IPO market, reducing reliance on single regions.
Economic Policies
If monetary easing continues and geopolitical tensions reduce, IPO markets are likely to see further expansion in both number and value of offerings.
8. Conclusion
The global IPO market in the mid‑2020s has shifted from the uncertainty of the early 2020s to a phase of resilience and cautious expansion. While market volatility and external economic pressures remain challenges, structural improvements, stronger investor sentiment, and megadeals in promising sectors suggest a maturing market with significant future capital formation potential.
Whether for young innovators or established industrial firms, the IPO remains a central pillar of global capital markets—connecting companies with investors and driving growth across regions and industries.
IPO-INVEST
MEDANTA- NEXT DREAM RUN IPO !1.After listing rally stock formed good base with volume contraction ( first mature base)
2.Now stock trading in range from last breakout high ( forming second mature base)
3.Now closing above 530 with good volume will trigger next upmove
4. Stop loss - closing below upword slanting trendline
5. Target - 574/610/680+
Fundamentally good stock trading at the demand zone.Syrma SGS Technology gave a decent listing gain of 27-30% and thereafter went as high as 324 giving 78% returns.
This gem has corrected to 270 zones once from where it gained 38% and currently it is back at the demand zones of 270.
A Fundamentally good stock is available at nearly 50-60% less than its ATH. Can surely be accumulated for long and medium term.
KRSNAA DIAGNOSTICS PRICE ACTION ANALYSIS AND TARGETSKrsnaa diagnostics price needs to sustain 862 to prevent further breakdown.
If price action shows us any signs of bottoming at this level, buy.
if the price somehow reaches the demand zone created by the ABCD patterns, then buy the stock.
The targets are mentioned on the chart with the help of the XABCD bat pattern.
The stop loss will be as per your risk appetite.
Happy trading :)
This is just for educational purposes.
Tatva Chintan Pharma- China Plus one Theme?Tatva Chintan Pharma- Recent IPO - CMP 2250- Mcap 4989 Cr
There is no Margin of Safety Currently in Valuations if i look it as a Long Term bet.
However- Currently China Factor is Keeping Speciality Chemical Companies Afloat and Bouyant. As long as sentiments are good, Valuations can go Crazy.
Speciality Chemicals can be a good Theme to Trade.
Incorporated in 1996, Tatva Chintan Pharma Chem Limited is a chemical manufacturing company that manufactures structure directing agents (SDAs), phase transfer catalyst (PTCs), pharmaceutical and agrochemical intermediates, and other specialty chemicals. It is among the largest manufacturer of SDAs for zeolites in India.
The company serves customers across industries i.e. automotive, petroleum, agrochemicals, dyes and pigments, paints and coatings, pharmaceutical, personal care, and others. Its products are not only sold in India but also export to 25+ countries all over the world such as the USA, Germany, South Africa, China, and the UK. In FY 2020, total export contributed to 76% of total revenue from operations.
Merck, Bayer AG, Ipox Chemicals, Laurus labs, Navin Fluorine International Limited, Atul Limited, Otsuka Chemicals, SRF Limited, Hawks Chemical Company, Firmenich Aromatics Prod Pvt Ltd, and Divi's laboratories are a few of customers of the company. Currently, it has two manufacturing facilities at Ankleshwar and Dahej in Gujarat.
Competitive strengths
Leading manufacturer of structure directing agents and phase transfer catalyst.
Diversified product portfolio.
Global market presence with customer base across industries.
Strategically located manufacturing facility in Gujarat with close proximity to Hazira Port.
Experienced promoters and managers team.
Strong financial performance track record.
Company Promoters:
Ajaykumar Mansukhlal Patel, Chintan Nitinkumar Shah, and Snehkar Rasiklal Somani are the company promoters.
STOVEKRAFT BULLISH RECTANGLE BREAKOUTStovekraft price has seen a sharp rise from 783 to 1018 level and consolidated in a zone until recently.
The price has broken out the range with high volumes and took a pullback and rose today.
If the price manages to stay above 1068, the pullback will be a success, you can go long.
The stoploss and target levels are mentioned on the chart.
Happy trading :)
This is just for educational purposes.
STOVEKRAFTSwing TrAdE options:
After Box Break-Out now forming Descending Triangle Pattern, Depends on the break-Out stock moves further.
Current Price- 595
P/E- 23.8 (less among competitors)
Short time target: 650, 690
Med Time target: 730(Pole Extension)
Pros:
Company has reduced debt.
Company has delivered good profit growth of 30.97% CAGR over last 5 years
Debtor days have improved from 47.73 to 36.00 days.
Note:
Its revenue contribution was Kitchen Appliances (88%) and Home Appliances (12%) in FY20. The improved product mix resulted in profit expansion.
Happy Trading
Abd
NURECA | IPO Details ....Started @ 15 / FEB /2021 ( Today) 🎯NURECA IPO REVIEW-
Introduction to NURECA-
-Incorporated on 2nd November 2016 @Delhi.
-B2C Home healthcare and wellness product company.
-95% Revenue online.
-1 manufacturing unit-@Chandigarh.
-3 Brands.
What does the company do-
-company enables people with tools to effectively monitor chronic illness and upgrade their lifestyles.
-company engaged in the business of home healthcare and wellness products, which offers quality, durability, functionality, usability, and innovative designs.
-company tries to provides the home health care sector with innovation.
-Nureca company is the first digital company wherein they sell the products through online channel partners such as e-commerce players, distributors, and retailers.
The following brands are currently used by the Company-
-Dr. Trust: they provide the users to effectively monitor chronic illness and try to upgrade their lifestyle.
-Dr. Physio: This brand provides electric massagers, wheelchairs, and walkers.
-Trump: This brand provides the Mother and Child Care category.
NURECA PRODUCTS-
-Chronic Device Products- products such as blood pressure monitors, pulse oximeters, thermometers, nebulizers, self-monitoring glucose devices, humidifier ands teamers.
-Orthopedic Products-such as wheelchairs, walkers and physiotherapy electric massagers.
-Mother and Child Products- such as breast pumps, bottle sterilizers, bottle warmers, car seats and baby carrycots.
-Nutrition Supplements- such as fish oil, multivitamins, probiotics, biotin, apple cider and vinegar.
-Lifestyle Products- such as smart scales, aroma diffusers and fitness trackers.
NURECA'S Strength-
-Most of the products of NURECA is outsourced.
-Due to this their cost of production is low comparatively.
-Asset light model.
-It increased the production capacity.
-Bring product on semi-knocked down condition.
-V-shaped recovery.
-Nureca has a strong portfolio of products and a consistent focus on quality and innovation.
Financial Analysis-
-It has grown at a CAGR of 122.49%. As for the total assets, that has grown at a CAGR of 117.12%.
-The profits after tax, the growth rate is more moderate.
-Over the past three years, the net income has grown at a CAGR of 41.42%.
-The negative net cash flow from operating activities has grown at a CAGR of above 780%.
-the increasing burden of long-term debt. From Rs. 43 lakhs in 2019 to Rs. 9.77 crores in 2020 is an increase of over 2000%.
-If this debt burden continues to increase at this rate, it will create pressure on Nureca’s balance sheet.
-It was valued at Rs. 20,757 crores in 2019. By 2025, this market is expected to grow to Rs. 38,920.70 crores.
-It has grown from $24 billion in 2017 to $84 billion in 2021.
-In India especially, at least 33% of the population resorts to online shopping as opposed to conventional shopping outlets.
-Nutritional products, Rs. 17,840 crores in 2019 and it is expected to grow to Rs. 33,368 crores in 2025.
-Coming to the market for orthopedic products, in 2019, it was sized at Rs. 682.80 crores. This is expected to grow to Rs. 1,162.90 crores by 2025. The predicted CAGR, in this case, is 9.2%. The graph below shows the growing market
size over the years.
-The demand for chronic disease products is, of course, fairly inelastic in nature.
-Owing to the steadily increasing wave of chronic diseases, this demand is expected to rise in the future.
-By 2026, 12.5% of the population is expected to be geriatric in nature i.e. they will be above the age of 60. This means the demand for health-care products will only increase.
Business model-
-Nureca is a B2C company engaged in the business of home healthcare and wellness products,
-it offers quality, durability, functionality, usability and innovative designs.
-Voltas enables their customers with tools to help them monitor chronic illness and other diseases, to upgrade their lifestyle.
Risk-
-it faces stiff competition from organized and unorganized players, which leads to pricing pressure.
-it reduced margins and lower profitability.
-Home-health products are considered consumer-grade, due to concerns regarding the accuracy measures of products.
-The company does not enter into long-term contracts for the manufacturing of its products and any manufacturing-related disruption could seriously impact its business
-The company also depends heavily on its channel partners such as third-party e-commerce players, distributors, and retailers. Any failure to manage the distribution network efficiently will adversely affect its performance.
IPO details-
IPO Date February 15, 2021 to February 17, 2021
Issue Type Book Built Issue IPO
Issue Size Rs.100 Crore
Fresh Issue Rs.100 Crore
Face Value Rs.10 per equity share
IPO Price Rs.396 to Rs.400 per equity share
Market Lot 35 shares
MinOQ 35 shares
Listing At BSE, NSE
Promoter's holding-
-Saurabh Goyal 46.67%
-Payal Goyal 46.67%
Object of the issue-
-To meet the working capital requirements of the business.
-To meet the general corporate purpose.
🙏FOLLOW for more !
👍LIKE if think is useful !
✍COMMENT Below your view !











